Marketa Skala

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial

David Ball, Shalini Vinod, Scott Babington et al. · The Lancet Oncology · 2019 · 584 citations

Medicine, Oncology, Radiation Oncology +13

Development of Indicators to Assess Quality of Care for Prostate Cancer

Nupur Nag, Jeremy Millar, Ian D. Davis et al. · European Urology Focus · 2016 · 87 citations · Full text

Medicine, Oncology, Urology +8

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)

Shankar Siva, Mathias Bressel, Tao Mai et al. · JAMA Oncology · 2021 · 87 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group

Hester Lieng, Amy Hayden, David Christie et al. · Radiotherapy and Oncology · 2018 · 62 citations

Medicine, Radiation Oncology, Urology +11

Patient-Assessed Late Toxicity Rates and Principal Component Analysis After Image-Guided Radiation Therapy for Prostate Cancer

Marketa Skala, Tara Rosewall, Laura A. Dawson et al. · International Journal of Radiation Oncology*Biology*Physics · 2007 · 55 citations

Medicine, Oncology, Radiation Oncology +17